125 related articles for article (PubMed ID: 12206475)
1. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases.
Gupta RK; Chhabra SK
Indian J Chest Dis Allied Sci; 2002; 44(3):165-72. PubMed ID: 12206475
[TBL] [Abstract][Full Text] [Related]
2. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
3. [Lung function and exercise tolerance after treatment with salmeterol or ipratropium bromide in chronic obstructive pulmonary disease].
Grzanka A; Pitsch T; Krzywiecki A; Rogala B
Pol Merkur Lekarski; 2004 Sep; 17(99):208-11. PubMed ID: 15628041
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
[TBL] [Abstract][Full Text] [Related]
5. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD.
Corda L; Bertella E; La Piana GE; Boni E; Redolfi S; Tantucci C
Respiration; 2008; 76(1):61-8. PubMed ID: 18319586
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
8. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
9. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
10. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
11. Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
Murali PM; Rajasekaran S; Paramesh P; Krishnarajasekar OR; Vasudevan S; Nalini K; Lakshmisubramanian S; Deivanayagam CN
Respir Med; 2006 Jan; 100(1):39-45. PubMed ID: 15905081
[TBL] [Abstract][Full Text] [Related]
12. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
13. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of salmeterol in stable COPD.
Kaushik ML; Kashyap S; Bansal SK; Sharma A
Indian J Chest Dis Allied Sci; 1999; 41(4):207-12. PubMed ID: 10661008
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
16. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
Make B; Hanania NA; ZuWallack R; Kalberg C; Emmett A; Brown CP; Knobil K
Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
[TBL] [Abstract][Full Text] [Related]
18. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
19. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease.
Covelli H; Bhattacharya S; Cassino C; Conoscenti C; Kesten S
Pharmacotherapy; 2005 Dec; 25(12):1708-18. PubMed ID: 16305289
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
